来那度胺或硼替佐米方案在老年浆细胞骨髓瘤患者中的结局
该研究利用2007至2015年Medicare受益人的真实世界数据,比较了RVD、RD、VD及VCD一线方案在老年骨髓瘤患者中的生存、不良事件和费用。RVD较双药方案显著改善OS和EFS,但住院、贫血和神经病变更多且费用更高;RD较VD的EFS更优,但血栓栓塞事件更多;VCD与VD无显著差异。
要点
- RVD较RD/VD双药方案显著改善OS和EFS。
- RVD增加住院、贫血和神经病变风险,费用更高。
- RD较VD的EFS更优,但血栓栓塞事件更多。
核心结论
- 对于老年浆细胞骨髓瘤患者,RVD方案较双药方案显示生存优势。
- RD可能优于VD作为双药方案选择,但需注意血栓栓塞风险。
- VCD较VD无生存获益。
研究设计与样本
- 回顾性队列研究,使用2007-2015年Medicare受益人真实世界数据。
- 共纳入6076例患者,中位年龄76岁,中位OS为2.6年。
- 采用倾向性评分平衡混杂因素,比较RVD vs RD/VD、RD vs VD、VCD vs VD。
主要发现
- RVD vs RD/VD双药:OS HR=0.83(95%CI 0.72-0.95),EFS HR=0.68(95%CI 0.61-0.76)。
- RD vs VD:EFS HR=0.74(95%CI 0.68-0.81),OS HR=0.91(95%CI 0.83-0.99)。
- VCD vs VD:所有结局均无显著差异。
- RVD组住院、贫血和神经病变更常见,但血栓栓塞和二次癌症未增加。
- RD组血栓栓塞事件显著更多,神经病变较少,住院、输血和二次癌症无显著差异。
关键数值与推荐
- RVD较双药方案OS HR=0.83(95%CI 0.72-0.95),EFS HR=0.68(95%CI 0.61-0.76)。
- RD较VD EFS HR=0.74(95%CI 0.68-0.81),OS HR=0.91(95%CI 0.83-0.99)。
- 2015年仅约25%的Medicare受益人接受RVD治疗。
临床怎么用
- 对于适合的老年骨髓瘤患者,优先考虑RVD方案以改善生存。
- 因毒性不适合RVD者,VCD较VD无生存获益,RD可能是更优双药选择。
- 使用RD时需关注血栓栓塞风险,使用RVD时需监测住院、贫血和神经病变。
局限性
- 真实世界回顾性研究,可能存在选择偏倚和混杂。
- 数据来源于Medicare受益人,结论外推需谨慎。
- 未报告RVD与双药方案比较的具体不良事件数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The "triplet" regimen of lenalidomide, bortezomib, and dexamethasone (RVD) showed survival advantage over lenalidomide-dexamethasone (RD) in clinical trials, but older patients with myeloma often receive doublet regimens (RD or bortezomib-dexamethasone, VD), or VD plus cyclophosphamide (VCD). We compared these first-line regimens using real-world data from Medicare beneficiaries receiving therapy between 2007 and 2015. In each comparative analysis, we balanced confounding characteristics using a propensity score. Outcomes included overall (OS) and event-free survival (EFS, reporting hazard ratios [HR] with 95% confidence intervals [CI]), adverse events, and costs. We identified 6076 patients with median age 76 and median OS of 2.6 years. In the comparison of RVD vs RD/VD doublets, RVD showed significantly better OS (HR = 0.83; 95% CI, 0.72-0.95) and EFS (HR = 0.68; 95% CI, 0.61-0.76). So, RVD was associated with more frequent hospitalizations, anemia, and neuropathy, but no increase in thromboembolism or secondary cancers. Costs were higher with RVD. In the comparison of RD vs VD, RD demonstrated better EFS (HR = 0.74; 95% CI, 0.68-0.81) and marginally better OS (HR = 0.91; 95% CI, 0.83-0.99). And, RD resulted in significantly more thromboembolic events, less neuropathy, and no significant difference in hospitalizations, transfusions, or secondary cancers. In the comparison of VCD vs VD, we observed no significant difference in any outcome. Superior survival favors RVD over doublet regimens, but even in 2015 RVD was applied for only about 25% of Medicare beneficiaries with myeloma. For patients not eligible for RVD due to toxicity, VCD offers no survival benefit over VD. Lenalidomide-dexamethasone may be the preferred line doublet considering its advantage over VD.
引用
- Barth P, Giri S, Reagan JL, et al. Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma. Am J Hematol. 2020. PMID: 32918301. doi:10.1002/ajh.25996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。